The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-50 and 50-70 years old.
PICOBOO randomized trial, evaluating second boosters after mRNA priming. 1) novavax is more durable 2) mRNA vaccines have higher antibody responses 3) novavax has fewer side effects
Pfizer antibody levels drop around 40% between 1 month to 3 months post vax. Moderna is less, w/ a 14% drop in younger adults, 26% decline in older adults. Novavax had only a 3% decline in younger adults and 17% in older adults.